Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK | Subject: Prothyx
Edited by the Laboratorytalk Editorial
Team on 16 February 2006
Partnership for tumour-targeted therapy
Cancer Research Technology and Stealthyx Therapeutics, a spin out of Queen Mary, University of London have entered into agreement to co-develop Stealthyx's proprietary drug delivery platform, Prothyx
The Prothyx platform adds extra functionality to therapeutic molecules making them preferentially active at sites of disease Localising a drug's activity only to the diseased tissue promises to minimise adverse side effects on other tissues and may enable higher doses of drugs to be given less frequently
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
Cancer Research Technology (CRT) has obtained worldwide exclusive rights to develop and commercialise the Prothyx platform within the field of oncology and will perform in-house development of candidate Prothyx-based anti-cancer therapies.
Stealthyx will exploit developments arising from the programme in other therapeutic areas including rheumatoid arthritis.
Phil L'Huillier, director of business management at CRT, said: "In-licensing of promising technologies from commercial parties to accelerate the development of novel cancer therapies highlights our continued commitment to the realisation of cancer patient benefit".
Professor Yuti Chernajovsky, founder of Stealthyx Therapeutics and ARC chair of rheumatology at Queen Mary, University of London, said: "CRT's co-development support for Prothyx endorses the important potential of our technology in cancer, where there are great opportunities to improve patients' clinical outcomes, and minimise the distressing side effects of some cancer treatments.
"I look forward to working with our partners to help bring safer medicines to the market.".
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
